Need Help?

Tumour WES data for paired or relapsed neuroblastoma

Whole exome sequencing (WES) data was analysed for 81 neuroblastoma samples from 35 patients at different timepoints, including at diagnosis (D), post-chemotherapy (PC), and/or relapse (R). Seventy-five samples were sequenced using the Illumina TruSeq Rapid Exome kit and NextSeq500 platform at 90x, while the Nextera Library Prep Kit and Illumina’s NovaSeq platform at 90x was used for the 6 remaining samples. Somatic variants were called using GATK HaplotypeCaller v. 4.0.11.0. VCF files from the analyses are included in this dataset.

Request Access

DUO:0000026
version: 2021-02-23

user specific restriction

This data use modifier indicates that use is limited to use by approved users.

VIVO Biobank Samples Data Access Policy

VIVO Biobank Samples Data Access Policy 1. Introduction This policy governs access to the genomic and phenotypic data from the VIVO Biobank Group studies deposited at the European Genome-phenome Archive (EGA). The data was collected for the purpose of genetic studies on childhood cancers. 2. Data Access Committee (DAC) Access to the data is managed by Newcastle University on behalf of the VIVO Biobank through the VIVO project specific Data Access Committee. Decisions on access are made exclusively based on scientific and ethical criteria in compliance with the original informed consent. 3. Terms of Access To request access, users must: • Be a bona fide researcher affiliated with a recognized research institution. • Provide a brief Research Project Description (max 500 words). • Submit a signed Data Access Agreement (DAA), which is a legally binding contract between the requester's institution and the DAC. 4. Permitted Use Data use is restricted based on the GA4GH Data Use Ontology (DUO) codes assigned to this dataset: • US (user-specific): This data use modifier indicates that use is limited to use by approved users. • Re-identification Prohibited: Requesters must agree not to attempt to re-identify any individual participant. • For additional clinical data, collaboration with members of the DAC is required. 5. Data Security Requirements Users must implement technical safeguards, including: • Storage on secure institutional computer systems behind a firewall. • Encryption of data if stored on portable devices (e.g., USB keys). • Access limited to authorized personnel listed in the DAA. 6. Publication & Acknowledgment Users must acknowledge the VIVO Biobank, members of the DAC, and the EGA in any resulting publications, citing the specific study accession number.

Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.

Study ID Study Title Study Type
EGAS50000002000 Cancer Genomics

This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.

ID File Type Size Quality Report
Located in
EGAF50000905650 vcf 21.3 MB Report
EGAF50000905651 vcf 18.4 MB Report
EGAF50000905669 vcf 18.5 MB Report
EGAF50000905670 vcf 17.2 MB Report
EGAF50000932156 vcf 18.7 MB Report
EGAF50000932157 vcf 20.8 MB Report
EGAF50000932158 vcf 16.8 MB Report
EGAF50000932159 vcf 21.7 MB Report
EGAF50000932160 vcf 19.5 MB Report
EGAF50000932161 vcf 18.4 MB Report
EGAF50000932162 vcf 14.2 MB Report
EGAF50000932163 vcf 18.6 MB Report
EGAF50000932164 vcf 19.2 MB Report
EGAF50000932165 vcf 13.4 MB Report
EGAF50000932166 vcf 21.3 MB Report
EGAF50000932167 vcf 19.0 MB Report
EGAF50000932168 vcf 14.5 MB Report
EGAF50000932169 vcf 14.9 MB Report
EGAF50000932170 vcf 17.7 MB Report
EGAF50000932171 vcf 16.7 MB Report
EGAF50000932172 vcf 21.8 MB Report
EGAF50000932173 vcf 19.5 MB Report
EGAF50000932174 vcf 19.4 MB Report
EGAF50000932175 vcf 14.2 MB Report
EGAF50000932176 vcf 19.0 MB Report
EGAF50000932177 vcf 19.5 MB Report
EGAF50000932178 vcf 18.1 MB Report
EGAF50000932179 vcf 21.1 MB Report
EGAF50000932180 vcf 13.7 MB Report
EGAF50000932181 vcf 18.3 MB Report
EGAF50000932182 vcf 21.6 MB Report
EGAF50000932183 vcf 20.8 MB Report
EGAF50000932184 vcf 20.9 MB Report
EGAF50000932185 vcf 17.3 MB Report
EGAF50000932186 vcf 18.8 MB Report
EGAF50000932187 vcf 19.1 MB Report
EGAF50000932188 vcf 15.7 MB
EGAF50000932189 vcf 16.7 MB Report
EGAF50000932190 vcf 18.5 MB Report
EGAF50000932191 vcf 20.2 MB Report
EGAF50000932192 vcf 18.4 MB Report
EGAF50000932193 vcf 15.2 MB
EGAF50000932194 vcf 18.0 MB Report
EGAF50000932195 vcf 19.2 MB Report
EGAF50000932196 vcf 18.8 MB Report
EGAF50000932197 vcf 16.9 MB Report
EGAF50000932198 vcf 15.6 MB
EGAF50000932199 vcf 17.6 MB Report
EGAF50000932200 vcf 18.3 MB Report
EGAF50000932201 vcf 18.2 MB Report
EGAF50000932202 vcf 19.7 MB Report
EGAF50000932203 vcf 19.2 MB Report
EGAF50000932204 vcf 16.8 MB Report
EGAF50000932205 vcf 19.1 MB Report
EGAF50000932206 vcf 18.8 MB Report
EGAF50000932207 vcf 13.4 MB Report
EGAF50000932208 vcf 13.5 MB Report
EGAF50000932209 vcf 10.9 MB Report
EGAF50000932210 vcf 20.7 MB Report
EGAF50000932211 vcf 14.7 MB Report
EGAF50000932212 vcf 14.8 MB Report
EGAF50000932213 vcf 15.0 MB
EGAF50000932214 vcf 14.9 MB
EGAF50000932215 vcf 18.0 MB Report
EGAF50000932216 vcf 15.8 MB Report
EGAF50000932217 vcf 18.0 MB Report
EGAF50000932218 vcf 18.1 MB Report
EGAF50000932219 vcf 19.3 MB Report
EGAF50000932220 vcf 19.2 MB Report
EGAF50000932221 vcf 17.5 MB Report
EGAF50000932222 vcf 20.9 MB Report
EGAF50000932223 vcf 17.2 MB Report
EGAF50000932224 vcf 20.3 MB Report
EGAF50000932225 vcf 17.7 MB Report
EGAF50000932226 vcf 18.3 MB Report
EGAF50000932231 vcf 45.2 MB Report
EGAF50000932232 vcf 43.1 MB Report
EGAF50000932233 vcf 45.7 MB Report
EGAF50000932234 vcf 39.9 MB Report
EGAF50000932235 vcf 34.3 MB Report
EGAF50000932236 vcf 39.2 MB Report
81 Files (1.6 GB)